G01N 2333/70592
Cd52
G01N2333/70592 (Cd52) appears on 12 US grants and 17 published applications in this corpus.
Search patents in G01N- Granted patents
- 12
- Published applications
- 17
- Assignees
- 5
- Inventors
- 24
- Latest grant
- 31 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2009 | 0 | 1 |
| 2010 | 0 | 1 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 1 |
| 2014 | 0 | 1 |
| 2015 | 0 | 1 |
| 2016 | 0 | 0 |
| 2017 | 3 | 5 |
| 2018 | 2 | 1 |
| 2019 | 3 | 1 |
| 2020 | 1 | 2 |
| 2021 | 1 | 0 |
| 2022 | 0 | 0 |
| 2023 | 1 | 3 |
| 2024 | 0 | 0 |
| 2025 | 0 | 0 |
| 2026 | 1 | 0 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Flare (flow cytometry attenuated reporter expression) technology for rapid bulk sorting31 Mar 2026US 12,590,880 B2Genzyme Corporation
- FLARE (flow cytometry attenuated reporter expression) technology for rapid bulk sorting25 Apr 2023US 11,635,363 B2Genzyme Corporation
- Soluble mediator21 Sep 2021US 11,123,403 B2The Walter and Eliza Hall Institute of Medical Research
- Method of identifying risk for thyroid disorder12 May 2020US 10,648,986 B2Genzyme Corporation
- Soluble mediator17 Sep 2019US 10,413,589 B2The Walter and Eliza Hall Institute of Medical Research
- Flare (flow cytometry attenuated reporter expression) technology for rapid bulk sorting28 Sep 2023US 2023/0304913 A1Genzyme Corporation
- Methods for detecting lung cancer24 Aug 2023US 2023/0266325 A1
- Breast cancer biomarkers and methods of use17 Aug 2023US 2023/0257825 A1City of Hope
- Soluble Mediator12 Mar 2020US 2020/0078440 A1The Walter and Eliza Hall Institute of Medical Research
- Early post-transfection isolation of cells (epic) for biologics production16 Jan 2020US 2020/0018682 A1Genzyme Corporation
Most cited
By later US patents
- Early post-transfection isolation of cells (EPIC) for biologics production3US 10,317,329 B2Genzyme Corporation · 2019
- Soluble mediator2US 10,010,582 B2The Walter and Eliza Hall Institute of Medical Research · 2018
- Soluble mediator2US 9,585,969 B2The Walter and Eliza Hall Institute of Medical Research · 2017
- Method of treating sepsis by administering a soluble CD52 glycoprotein2US 9,778,269 B2The Walter and Eliza Hall Institute of Medical Research · 2017
- Soluble mediator1US 10,413,589 B2The Walter and Eliza Hall Institute of Medical Research · 2019